464results about How to "Good antigenicity" patented technology

A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R1 and R2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R1 or R2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

The present invention relates to the display of antigenic or allergenic components along with a tissue-targeting component on viruses or virus-like particles. Capsid protein genes are recombinantly modified to contain the specified components then expressed within a host organism, such as yeasts, bacteria, or algae, and allowed to spontaneously form active virus particles or virus-like particles. The recombinant complexes (virus or virus-like particle) can then be purified or used in situ as a therapeutic tool for disease or allergy prevention. The expression of multivalent and multifunctional components to increase the immunogenicity of the recombinant complexes, especially on oral administration, is provided.

The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (alpha2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or alpha2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or alpha2M-antigenic molecule complex.

The invention relates to a medical flocking hemostasis material for stopping bleeding and protecting arteries, veins and wounds of tissues, application of the medical flocking hemostasis material and a method for preparing the medical flocking hemostasis material. The medical flocking hemostasis material comprises a flocking layer and a base layer, the flocking layer is used as a wound contacting layer and made of functional fibers, and the functional fibers are fixed on the upper surface of the base layer in a flocking method. The flocking method comprises a mechanical flocking method and an electrostatic flocking method. The medical flocking hemostasis material can be used for stopping bleeding and protecting the arteries, the veins and the wounds of the tissues, and further can be used as a medicine slow-release carrier. The invention further discloses method for controlling bleeding of the arteries, bleeding of the veins and bleeding of the wounds of the tissues by the aid of the medical flocking hemostasis material. Compared with a hemostasis material in the prior art, the medical flocking hemostasis material has the advantages that a hemostasis performance, comfortableness and the like are greatly improved.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.

A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

The invention discloses an Asia I type foot and mouth disease virus-like particle, a preparation method and an application thereof. The Asian I type foot and mouth disease virus-like particle comprises structural proteins of VP0, VP3 and VP1 of Asia I type foot and mouth disease virus, wherein the gene sequence of VP0 is shown in SEQ 1, the gene sequence of VP3 is shown in SEQ 3, and the gene sequence of VP1 is shown in SEQ 2. The preparation method of the Asian I type foot and mouth disease virus-like particle has the following steps: performing amplification to obtain the VP0, VP3 and VP1, performing enzyme digestion to obtain a recombinant expression vector, performing enzyme digestion on fusion protein by small ubiquitin-like modifier (SUMO), and carrying out in-vitro assembling to obtain the foot and mouth disease virus-like particle.

Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

The present invention discloses one kind of injected bone repairing material and its preparation and application. The injected bone repairing material consists of solution I and solution II, the solution I is the mixture of platelet rich plasma (PRP) and 80-100 mg/ml concentration fibrinogen solution in the ratio of 1 to 3-6; and the solution II is solution mixture of calcium chloride in 40 mmol/ml concentration and thrombin in 400-1000 U/ml concentration. When the injected bone repairing material is used, solution I and solution II in the volume ratio of 1-9 are sucked with two syringes and injected into body to form gel with high adhesive force, with PRP accounting for 10-30 vol%. The injected bone repairing material is used in preparing implant for treating bone defect and bone nonunion and promoting fracture healing.

The invention discloses an indirect ELISA diagnosing reagent box for pig II type circular virus (PCV2) antibody. There arranged with antibody detecting board in the reagent box, enzyme combination liquid, positive comparison, negative comparison, sample diluter, 10X condensed detergent, developing liquid A and B, and stopping liquid, the detecting board of the reagent box is removable 96-apertures enzyme labeling board enclosed with PCV2 reconstructed enucleation localizing signal capsid protein (dCap), the enzyme combination liquid is goat-anti-pig IgG multi-clone antibody labeled with HRP, the positive comparison is pig PCV 2 standard positive serum, the negative comparison is pig standard negative serum. The sensitivity of the invention is high, simple, and easy to be wide applied.

The invention discloses a Korean novel duck hepatitis viral antibody ELISA (Enzyme-Linked Immunosorbent Assay) detection kit. The detection kit contains an ELISA board coated by Korean novel duck hepatitis VP1 (Phenotypic Variance1) recombination protein, a sample diluent, concentrated washing liquid, an enzyme conjugate working solution, a chromogenic reagent (A), a chromogenic reagent (B), a stopping solution, a positive contrast solution and a negative contrast solution. The VP1 recombination protein is obtained by using the following method: using Korean novel duck hepatitis viruses as a material, augmenting and cloning the VP1 gene through an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) method to obtain recombinant expression plasmid pMD (physical medium dependent)-VP1; then, directionally inserting to an expression vector pET-32a (+) and screening to obtain recombinant expression plasmid pET-32a(+)-VP1; and inducing, expressing and purifying by ITPG (Isopropyl beta-D-Thiogalactopyranoside) to obtain VP1 recombination protein. The detection kit is used for detecting the Korean novel duck hepatitis and has strong specificity, high sensitivity, simplicity of operation, easiness of popularization and application in a large-area range and wide market prospects.

Disclosed are methods for treating cancers, particularly tumorigenic types. Cancer cells are modified to express highly immunogenic antigens so that the cells will generate a defensive response in a mammal that exhibits the cancer or is predisposed to cancer and prevent or ameliorate proliferation of cancer cells. The novel cancer cell vaccines are expected to be effective against a wide range of tumors and leukemias.

The invention relates to a method for preparing peony polypeptide from cake meal which is obtained through preparing peony seed oil by squeezing peony seeds, the polypeptide prepared by the method and application of the polypeptide. During the preparation of the polypeptide, various microbes are added to ferment or various proteases are added to be subjected to enzymolysis, so as to obtain the peony polypeptide product. The product can be in the form of powder, granules, tablets, capsules, oral liquid and the like. The peony polypeptide has the efficacy advantages of lowering cholesterol, lowering blood pressure, promoting fat metabolism, resisting fatigue, enhancing human immunity, regulating human physiological functions and the like and has broad development and application prospect in the fields of food industry, health care, medicine and the like.

The invention discloses a genotype VII Newcastle disease virus marker vaccine strain and an application thereof, and belongs to the field of genotype VII Newcastle disease virus marker vaccine strain rescue and application. A built Newcastle disease virus reverse genetic operating platform is utilized for enabling NP protein of a G7 strain to miss 18 amino acids and conducting mutation on F-protein cleavage loci, and the highly-weak virulence and high-virus titer genotype VII Newcastle disease virus marker vaccine strain MG7-NPdelta18+Fmut is rescued through screening. The microbial preservation serial number is CCTCC NO: V201505. The marker vaccine strain has the biological characteristics of high growth titer and low virulence in chick embryos and is genetically stable. The immune protection test result shows that the marker vaccine strain is good in immunogenicity, capable of inducing high-level protective antibodies, and capable of completely protecting immunized chicken, can be used for preventing and controlling a currently-popular genotype VII Newcastle disease virus and lays the foundation of identifying vaccine immunity and wild virus infection.

The invention relates to a human AD7C-NTP antigen determinant polypeptide antibody and the application on a diagnosis reagent case. The AD7C-NTP antigen determinant polypeptide of the invention is one of polypeptide sections which are stated by the sequence table SEQ ID NO.1 to SEQ ID NO.6. The antibody of the invention is prepared by any AD7C-NTP antigen determinant polypeptide of the invention. The AD7C-NTP antibody of the invention can be applied to prepare an AD7C-NTP external diagnosis reagent case.

The invention relates to a syphilis serological screening or diagnosis method. The purpose is that the method has the characteristics of low price, high speed, sensitivity and specificity. The technical scheme provided by the invention is that: a preparation method of rTpN15-17-47-ELISA for detecting syphilis serum antibodies comprises the following steps in turn: constructing an artificial fusion gene tpN15-17-47 of tpN15, tpN17 and tpN47 and a prokaryotic expression system E.coliBL21DE3Pet42a-tpN15-17-47 by gene technology, purifying the recombinant expression product rTpN15-17-47 as a coating antigen, establishing rTpN15-17-47-ELISA for detecting syphilis serum antibodies. The fusion gene tpN15-17-47 has a nucleotide sequence and an amino acid sequence as shown in sequence table 5.

The invention discloses an indirect enzyme-linked immuno sorbent assay (ELISA) kit for detecting avian infectious bronchitis virus (IBV) antibody. The kit contains an ELISA plate enveloped by IBV-N recombinant protein serving as antigen. The IBV-N recombinant protein is obtained by the following method: designing a pair of specific primers according to an IBV-N gene sequence; amplifying the N gene of IBV by using a reverse transcription polymerase chain reaction (RT-PCR) method, directionally inserting the N gene into a pET-32a(+) expression vector, and screening to obtain a positive recombinant expression plasmid of pET-32a(+)-IBV-N; and transferring the plasmid to a BL21 competent cell, and performing isopropyl thiogalactoside (ITPG) induction expression to obtain the IBV-N recombinant protein. The kit is low in cost, easy, convenient and quick to operate, and particularly suitable for detecting batch samples, and greatly improves the efficiency of serodiagnosis of the avian infectious bronchitis.

Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

The invention discloses a making method of heavy-metal lead monoclonal antibody in the biological technical domain, which is characterized by the following: coupling lead ion and carrier protein through p-aminobenzene-diethylenetriamine pentoacetic acid as bifunctional metal chelant; obtaining full antigen; crossing splenocyte and Sp2/0 marrow tumour cell to make crossed tumour cell; sieving; obtaining stable strong secretory specificity anti-lead monoclonal monomer to inhibit Pb-DTPA.

The present invention relates to a preparation method of heavy metal mercury monoclonal antibody, which belongs to the field of biotechnology. The present invention is particularly used in the preparation of specificity-recognition heavy metal mercury monoclonal antibody and in the fast mercury high-sensitivity measurement remained in the agricultural production and the agricultural production environment. The heavy metal mercury ion and the carrier albumen are coupled into full antigens through bifunctional metal chelate 1-(4-separate-cyano phenyl)-EDTA; the full antigens are used on Balb/C mouse and the spleen cells and the Sp2/0 myeloma cells are used to prepare hybridoma cells through the hybridoma technology. And monoclonal antibody which can stably excrete anti-Hg-EDTA is generated. The preparation technology in the present invention is easy and practical: the whole preparation process of the antigen requires no special instrument. The present invention is suitable for factory-scale production.

The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient a compound of the invention or a salt thereof, or a composition comprising the same.